dalteparin has been researched along with Cardiovascular Pregnancy Complications in 110 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Antepartum prophylactic dalteparin does not reduce the occurrence of venous thromboembolism, pregnancy loss, or placenta-mediated pregnancy complications in pregnant women with thrombophilia at high risk of these complications and is associated with an increased risk of minor bleeding." | 9.19 | Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. ( Chan, WS; Clement, AM; Coat, S; Demers, C; Dwyer, J; Greer, IA; Hague, WM; Hinshaw, K; Kahn, SR; Karovitch, A; Keely, E; Khandelwal, M; Khurana, R; Kingdom, J; Kovacs, MJ; Le Gal, G; McDonald, S; McLeod, A; Newstead-Angel, J; Rey, E; Robinson, S; Rodger, MA; Rosene-Montella, K; Said, J; Sermer, M; Silver, RM; Smith, G; Solymoss, S; Walker, M; Wells, PS, 2014) |
| "Dalteparin dosing, based on weight alone, every 12 hours is inadequate to maintain most pregnant women in the therapeutic range throughout pregnancy as measured by anti-Xa activity." | 9.11 | A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. ( Barbour, LA; Oja, JL; Schultz, LK, 2004) |
| "A systematic review of studies published between 1 January 1985 and 31 August 2017 was performed to analyse the efficacy of the low-molecular-weight heparin, dalteparin, in venous thromboembolism (VTE) treatment and prophylaxis during pregnancy, and to evaluate dosing practices, anticoagulant monitoring and adverse events." | 9.01 | Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy. ( Hellgren, M; Mistafa, O, 2019) |
| "Even though the use of acenocoumarol throughout pregnancy replaced by LMWH in the 1st trimester was proven safe and efficacious in this case report, large randomized controlled studies are still needed to make definitive recommendations about optimal antithrombotic therapy in pregnant patients with mechanical heart valves." | 7.75 | Acenocoumarol and pregnancy outcome in a patient with mitral valve prosthesis: a case report. ( Antsaklis, A; Daskalakis, G; Loutradis, D; Papoutsis, D; Stefanidis, K, 2009) |
| "To evaluate the effect and dose of dalteparin given to pregnant women with acute venous thromboembolism." | 7.72 | Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. ( Jacobsen, AF; Qvigstad, E; Sandset, PM, 2003) |
| "Under the therapy with LMWH (dalteparin-Na), no thromboembolic events during pregnancy or post partum could be observed." | 7.71 | [Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy]. ( Bahlmann, F; Himmrich, L; Klotz, M; Peetz, D; Savvidis, S; Schinzel, H, 2002) |
| "Antepartum prophylactic dalteparin does not reduce the occurrence of venous thromboembolism, pregnancy loss, or placenta-mediated pregnancy complications in pregnant women with thrombophilia at high risk of these complications and is associated with an increased risk of minor bleeding." | 5.19 | Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. ( Chan, WS; Clement, AM; Coat, S; Demers, C; Dwyer, J; Greer, IA; Hague, WM; Hinshaw, K; Kahn, SR; Karovitch, A; Keely, E; Khandelwal, M; Khurana, R; Kingdom, J; Kovacs, MJ; Le Gal, G; McDonald, S; McLeod, A; Newstead-Angel, J; Rey, E; Robinson, S; Rodger, MA; Rosene-Montella, K; Said, J; Sermer, M; Silver, RM; Smith, G; Solymoss, S; Walker, M; Wells, PS, 2014) |
| "Dalteparin dosing, based on weight alone, every 12 hours is inadequate to maintain most pregnant women in the therapeutic range throughout pregnancy as measured by anti-Xa activity." | 5.11 | A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. ( Barbour, LA; Oja, JL; Schultz, LK, 2004) |
| "A systematic review of studies published between 1 January 1985 and 31 August 2017 was performed to analyse the efficacy of the low-molecular-weight heparin, dalteparin, in venous thromboembolism (VTE) treatment and prophylaxis during pregnancy, and to evaluate dosing practices, anticoagulant monitoring and adverse events." | 5.01 | Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy. ( Hellgren, M; Mistafa, O, 2019) |
| " My physician recommended I use dalteparin during this pregnancy although, during my previous pregnancy, I had received subcutaneous heparin injections three times daily." | 4.82 | Low-molecular-weight heparins during pregnancy. ( Koren, G; Many, A, 2005) |
| "Even though the use of acenocoumarol throughout pregnancy replaced by LMWH in the 1st trimester was proven safe and efficacious in this case report, large randomized controlled studies are still needed to make definitive recommendations about optimal antithrombotic therapy in pregnant patients with mechanical heart valves." | 3.75 | Acenocoumarol and pregnancy outcome in a patient with mitral valve prosthesis: a case report. ( Antsaklis, A; Daskalakis, G; Loutradis, D; Papoutsis, D; Stefanidis, K, 2009) |
| " Pregnancy and fetal outcomes included miscarriage, stillbirth, baby death and live birth, small-for-gestational-age infants, warfarin embryopathy and warfarin-related fetal loss." | 3.75 | Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. ( McCowan, LM; McLintock, C; North, RA, 2009) |
| "To evaluate the effect and dose of dalteparin given to pregnant women with acute venous thromboembolism." | 3.72 | Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. ( Jacobsen, AF; Qvigstad, E; Sandset, PM, 2003) |
| "This prospective audit reports pregnancy outcomes, anticoagulation complications, and anti-Xa levels in women with mechanical heart valves who were treated with therapeutic enoxaparin plus aspirin during pregnancy." | 3.71 | Enoxaparin treatment in women with mechanical heart valves during pregnancy. ( McCowan, LM; North, RA; Raudkivi, PJ; Rowan, JA, 2001) |
| "Under the therapy with LMWH (dalteparin-Na), no thromboembolic events during pregnancy or post partum could be observed." | 3.71 | [Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy]. ( Bahlmann, F; Himmrich, L; Klotz, M; Peetz, D; Savvidis, S; Schinzel, H, 2002) |
| "Women were treated with enoxaparin with dosage adjustment to achieve a peak anti-Xa of 1." | 2.76 | A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves. ( Aziz, RH; Dominique, TG; Jacobson, BF; Pravin, M; Saeed, CR; Serasheini, M, 2011) |
| " We used American College of Obstetrics and Gynecology recommendations as the base for screening and dosing guidelines and utilized known and published absolute risk values and odds ratios to stratify risk factors." | 2.61 | Risk Assessment and Treatment Guide for Obstetric Thromboprophylaxis: Comprehensive Review of Current Guidelines. ( Deering, SH; Eubanks, AA; Thiel, LM, 2019) |
| "Idiopathic pulmonary arterial hypertension is a rare and progressive condition which is aggravated by the physiologic changes during pregnancy." | 2.58 | Pregnancy outcome in a pregnant patient with idiopathic Pulmonary Arterial Hypertension: a case report and review of the literature. ( Rashidi, F; Sate, H, 2018) |
| "High rates of postpartum hemorrhage are reported in our cohort." | 1.51 | Effectiveness and safety of thromboprophylaxis with enoxaparin for prevention of pregnancy-associated venous thromboembolism. ( Cox, S; Eslick, R; McLintock, C, 2019) |
| " We investigated two different dosing regimens; fixed dose and weight-adjusted dose on the anticoagulant effects of the LMWH tinzaparin used for thromboprophylaxis in obese pregnant women." | 1.40 | Weight-adjusted LMWH prophylaxis provides more effective thrombin inhibition in morbidly obese pregnant women. ( Higgins, JR; Ismail, SK; Norris, L; O'Shea, S, 2014) |
| "Untreated hereditary antithrombin deficiency in pregnancy is associated with maternal venous thromboembolism (VTE) and possibly with fetal loss." | 1.39 | How I treat heterozygous hereditary antithrombin deficiency in pregnancy. ( Bramham, K; Hunt, BJ; Mitchell, M; Moore, GW; Retter, A; Robinson, SE, 2013) |
| " For those records documenting tinzaparin use and pregnancy outcome, information was extracted into a standardised case report form; these were reviewed for adverse events, which were submitted for adjudication by independent experts in obstetric medicine and haematology." | 1.37 | Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. ( Borg, JY; Greer, IA; Nelson-Piercy, C; Powrie, R; Rodger, M; Stinson, J; Talbot, DJ, 2011) |
| "The optimal treatment of pregnancy associated VTE (venous thromboembolism) has not been established yet." | 1.36 | Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium. ( Antonijević, N; Djordjević, V; Ilić, V; Kovac, M; Lazić, R; Mitić, G; Novakov-Mikić, A; Povazan, L; Salatić, I, 2010) |
| "Given that deep vein thrombosis coincided with obstetric delivery, it was crucial to decide on anesthetic and therapeutic approaches that would assure maternal and fetal safety and prevent such complications as massive pulmonary thromboembolism." | 1.36 | [Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery]. ( Amorós, B; Bermejo, L; Dueñas, N; Fernández, E; Perea, M; Villafranca, A, 2010) |
| "The pregnancy was carried to term and she delivered a healthy boy at 38 weeks of gestation." | 1.36 | Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia. ( Corbi, P; Hajj-Chahine, J; Jayle, C; Tomasi, J, 2010) |
| "Individually dosed LMWH is well tolerated and safe for prophylaxis and treatment of thromboembolic complications during pregnancy, delivery and the postpartum period." | 1.36 | Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin. ( Andersen, AS; Bergholt, T; Berthelsen, JG, 2010) |
| "The recommended dosage of tinzaparin in the treatment of thromboembolism during pregnancy is 175 IU/kg/day, as for non-pregnant subjects." | 1.35 | Treatment of deep venous thrombosis in pregnant women. ( Grønlykke, T; Langhoff-Roos, J; Lykke, JA, 2008) |
| " Anti-Xa levels may reflect inadequate dosing of low molecular weight heparin, particularly during the first trimester, and should be monitored frequently." | 1.33 | Budd-Chiari syndrome, systemic lupus erythematosus, and secondary antiphospholipid antibody syndrome in pregnancy. ( Aisenbrey, GA; Argubright, KF; Joffe, GM, 2005) |
| "We report a pregnant woman with systemic lupus erythematosus and recurrent venous thromboembolism who suffered from heparin-induced thrombocytopenia type II while treated with dalteparin sodium." | 1.31 | Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. ( Geberth, M; Harenberg, J; Heene, DL; Hoffmann, U; Huhle, G, 2000) |
| " One daily dosage of 5,000 IU anti-Xa resulted in a measurable level of FXa for 24 h in pregnancy week 40, compared with 17h at pregnancy week 37." | 1.31 | Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy. ( Blombäck, M; Bremme, K; van Rooijen, M; Yu, A, 2001) |
| "We studied the outcome of 41 pregnancies in an attempt to identify an appropriate and safe anticoagulant regimen for pregnant women with cardiac valve prosthesis." | 1.30 | Is there a safe anticoagulation protocol for pregnant women with prosthetic valves? ( Alam, SE; Arnaout, MS; Karam, K; Kazma, H; Khalil, A; Nasrallah, A; Shasha, N, 1998) |
| "We present a case of pulmonary embolism successfully treated with low molecular weight heparin in a woman with a major grade placenta praevia, who required emergency operative delivery." | 1.30 | Thromboembolism treated with low molecular weight heparin in a pregnancy complicated by major placenta praevia: a case report. ( Hertzberg, M; Lahoud, R; Nicholl, M; Rowlands, S, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (12.73) | 18.2507 |
| 2000's | 47 (42.73) | 29.6817 |
| 2010's | 47 (42.73) | 24.3611 |
| 2020's | 2 (1.82) | 2.80 |
| Authors | Studies |
|---|---|
| Mitić, G | 1 |
| Kovac, M | 1 |
| Povazan, L | 1 |
| Djordjević, V | 1 |
| Ilić, V | 1 |
| Salatić, I | 1 |
| Lazić, R | 1 |
| Antonijević, N | 1 |
| Novakov-Mikić, A | 1 |
| Bednarek, W | 1 |
| Karowicz-Bilińska, A | 1 |
| Kotarski, J | 1 |
| Nowak-Markwitz, E | 1 |
| Oszukowski, P | 1 |
| Paszkowski, T | 1 |
| Poreba, R | 1 |
| Spaczyński, M | 1 |
| Teliga-Czajkowska, J | 1 |
| Obergfell, A | 1 |
| Langenfeld, H | 1 |
| Hopp, H | 1 |
| Steigerwald, U | 1 |
| Grossmann, R | 1 |
| Jacquemyn, Y | 1 |
| Vercauteren, M | 1 |
| Lee, JH | 1 |
| Park, NH | 1 |
| Keum, DY | 1 |
| Choi, SY | 1 |
| Kwon, KY | 1 |
| Cho, CH | 1 |
| Schapkaitz, E | 1 |
| Jacobson, BF | 2 |
| Czestochowska, E | 1 |
| Arnaout, MS | 1 |
| Kazma, H | 1 |
| Khalil, A | 1 |
| Shasha, N | 1 |
| Nasrallah, A | 1 |
| Karam, K | 1 |
| Alam, SE | 1 |
| Tam, WH | 1 |
| Wong, KS | 1 |
| Yuen, PM | 1 |
| Leung, TN | 1 |
| Li, CY | 1 |
| Fontcuberta Boj, J | 1 |
| Kalçık, M | 1 |
| Güner, A | 1 |
| Kalkan, S | 1 |
| Özkan, M | 1 |
| Chuzi, S | 1 |
| Eucalitto, P | 1 |
| Yee, LM | 1 |
| Rashidi, F | 1 |
| Sate, H | 1 |
| Benatta, NF | 1 |
| Batouche, DD | 1 |
| Djazouli, MA | 1 |
| Eubanks, AA | 1 |
| Deering, SH | 1 |
| Thiel, LM | 1 |
| Einerson, BD | 1 |
| Branch, DW | 1 |
| Moriuchi, K | 1 |
| Chigusa, Y | 1 |
| Kondoh, E | 1 |
| Murakami, R | 1 |
| Ueda, Y | 1 |
| Mogami, H | 1 |
| Mandai, M | 1 |
| Garmi, G | 1 |
| Zafran, N | 1 |
| Okopnik, M | 1 |
| Gavish, I | 1 |
| Romano, S | 1 |
| Salim, R | 1 |
| Cox, S | 1 |
| Eslick, R | 1 |
| McLintock, C | 3 |
| Tardy, B | 1 |
| Buchmuller, A | 1 |
| Bistervels, IM | 1 |
| Ni Ainle, F | 1 |
| Middeldorp, S | 1 |
| Vijayan, V | 1 |
| Rachel, T | 1 |
| Bramham, K | 1 |
| Retter, A | 1 |
| Robinson, SE | 1 |
| Mitchell, M | 1 |
| Moore, GW | 1 |
| Hunt, BJ | 4 |
| Darmochwał-Kolarz, D | 1 |
| Chara, A | 1 |
| Korzeniewski, M | 1 |
| Leszczyńska-Gorzelak, B | 1 |
| Oleszczuk, J | 1 |
| Königsbrügge, O | 1 |
| Langer, M | 1 |
| Hayde, M | 1 |
| Ay, C | 1 |
| Pabinger, I | 1 |
| Patel, JP | 1 |
| Patel, RK | 1 |
| Roberts, LN | 1 |
| Marsh, MS | 1 |
| Green, B | 1 |
| Davies, JG | 1 |
| Arya, R | 1 |
| Rosengarten, D | 1 |
| Kramer, R | 1 |
| Ismail, AM | 1 |
| Hamed, AH | 1 |
| Saso, S | 1 |
| Abu-Elhasan, AM | 1 |
| Abu-Elghar, MM | 1 |
| Abdelmeged, AN | 1 |
| Fox, NS | 1 |
| Laughon, SK | 1 |
| Bender, SD | 1 |
| Saltzman, DH | 1 |
| Rebarber, A | 1 |
| Bernardon, M | 1 |
| Limone, A | 1 |
| Businelli, C | 1 |
| Maso, GP | 1 |
| Piccoli, M | 1 |
| Alberico, S | 1 |
| Stefanidis, K | 1 |
| Papoutsis, D | 1 |
| Daskalakis, G | 1 |
| Loutradis, D | 1 |
| Antsaklis, A | 1 |
| McCowan, LM | 2 |
| North, RA | 3 |
| Panni, JK | 1 |
| Panni, MK | 1 |
| Fernández, E | 1 |
| Dueñas, N | 1 |
| Villafranca, A | 1 |
| Perea, M | 1 |
| Amorós, B | 1 |
| Bermejo, L | 1 |
| Saeed, CR | 1 |
| Pravin, M | 1 |
| Aziz, RH | 1 |
| Serasheini, M | 1 |
| Dominique, TG | 1 |
| Gris, JC | 3 |
| Chauleur, C | 3 |
| Faillie, JL | 1 |
| Baer, G | 1 |
| Marès, P | 3 |
| Fabbro-Peray, P | 2 |
| Quéré, I | 3 |
| Lefrant, JY | 2 |
| Haddad, B | 2 |
| Dauzat, M | 3 |
| Hajj-Chahine, J | 1 |
| Jayle, C | 1 |
| Tomasi, J | 1 |
| Corbi, P | 1 |
| Sachithanandan, A | 1 |
| Amagada, JO | 1 |
| Pembridge, J | 1 |
| Misra, D | 1 |
| Aledort, L | 1 |
| Stock, SJ | 1 |
| Walker, MC | 1 |
| Edelshain, BT | 1 |
| Horn, L | 1 |
| Norman, JE | 1 |
| Denison, FC | 1 |
| Molinari, N | 1 |
| Ciçek Yilmaz, D | 1 |
| Büyükakilli, B | 1 |
| Yilmaz, AR | 1 |
| Gürgül, S | 1 |
| Smith, JS | 1 |
| Mueller, J | 1 |
| Daniels, CJ | 1 |
| Ng, WP | 1 |
| Yip, WL | 1 |
| Izaguirre, R | 1 |
| De La Peña, A | 1 |
| Ramírez, A | 1 |
| Cortina, E | 1 |
| Huerta, M | 1 |
| Salazar, E | 1 |
| Ginsberg, JS | 1 |
| Chan, WS | 2 |
| Bates, SM | 1 |
| Kaatz, S | 1 |
| Topol, EJ | 1 |
| Rowan, JA | 2 |
| Taylor, RS | 1 |
| Mercier, E | 1 |
| Lavigne-Lissalde, G | 1 |
| Cochery-Nouvellon, E | 1 |
| Hoffet, M | 1 |
| Ripart-Neveu, S | 1 |
| Tailland, ML | 1 |
| Gates, S | 1 |
| Brocklehurst, P | 1 |
| Ayers, S | 1 |
| Bowler, U | 1 |
| Aharon, A | 1 |
| Lanir, N | 1 |
| Drugan, A | 1 |
| Brenner, B | 1 |
| Joffe, GM | 1 |
| Aisenbrey, GA | 1 |
| Argubright, KF | 1 |
| Kinori, M | 1 |
| Saar, N | 1 |
| Justo, D | 1 |
| Almog, R | 1 |
| Quenet, S | 1 |
| Varlet, MN | 1 |
| Seffert, P | 1 |
| Laporte, S | 1 |
| Decousus, H | 1 |
| Mismetti, P | 1 |
| Camacho Pulido, JA | 1 |
| Jiménez Sánchez, JM | 1 |
| Montijano Vizcaíno, A | 1 |
| Jurado Lara, B | 1 |
| de Molina Ortega, A | 1 |
| Fernández-Meré, LA | 1 |
| Fernández Rogríguez, S | 1 |
| Alvarez-Blanco, M | 1 |
| Nelson-Piercy, C | 5 |
| Sturridge, F | 1 |
| de Swiet, M | 2 |
| Letsky, E | 1 |
| Phillips, JK | 1 |
| Majumdar, G | 1 |
| Savidge, GF | 2 |
| Macklon, NS | 1 |
| Greer, IA | 6 |
| Reid, AW | 1 |
| Walker, ID | 3 |
| Dulitzki, M | 2 |
| Pauzner, R | 2 |
| Langevitz, P | 2 |
| Pras, M | 1 |
| Many, A | 3 |
| Schiff, E | 1 |
| Letsky, EA | 1 |
| Ellis, MH | 1 |
| Nun, IB | 1 |
| Rathaus, V | 1 |
| Werner, M | 1 |
| Shenkman, L | 1 |
| Stephan, D | 1 |
| Welsch, M | 1 |
| Chapatte, D | 1 |
| Weltin, D | 1 |
| Imbs, JL | 1 |
| Bonnar, J | 3 |
| Norris, LA | 3 |
| Greene, R | 1 |
| Lev-Ran, O | 1 |
| Kramer, A | 1 |
| Gurevitch, J | 1 |
| Shapira, I | 1 |
| Mohr, R | 1 |
| Rocha, E | 1 |
| Panizo, C | 1 |
| Lecumberri, R | 1 |
| Ellison, J | 2 |
| Berndt, N | 1 |
| Khan, I | 1 |
| Gallo, R | 1 |
| Magdelaine, A | 1 |
| Verdy, E | 1 |
| Coulet, F | 1 |
| Berkane, N | 1 |
| Girot, R | 1 |
| Uzan, S | 1 |
| Soubrier, F | 1 |
| Thomson, AJ | 1 |
| Raudkivi, PJ | 1 |
| Livneh, A | 1 |
| Kenett, R | 1 |
| Askim, AJ | 1 |
| Thrane, AS | 1 |
| Giaever, P | 1 |
| Andersen, R | 1 |
| Krohn, J | 1 |
| Xiang, Y | 1 |
| Li, J | 1 |
| Sun, Y | 1 |
| Hellgren, M | 1 |
| Mistafa, O | 1 |
| Hecking, C | 1 |
| Hendelmeier, M | 1 |
| von Bardeleben, R | 1 |
| Gröschel, K | 1 |
| Schinzel, H | 3 |
| Gibson, PS | 1 |
| Nerenberg, KA | 1 |
| Rodger, MA | 2 |
| Hague, WM | 2 |
| Kingdom, J | 2 |
| Kahn, SR | 2 |
| Karovitch, A | 1 |
| Sermer, M | 1 |
| Clement, AM | 1 |
| Coat, S | 1 |
| Said, J | 1 |
| Rey, E | 1 |
| Robinson, S | 1 |
| Khurana, R | 1 |
| Demers, C | 1 |
| Kovacs, MJ | 1 |
| Solymoss, S | 1 |
| Hinshaw, K | 1 |
| Dwyer, J | 1 |
| Smith, G | 1 |
| McDonald, S | 1 |
| Newstead-Angel, J | 1 |
| McLeod, A | 1 |
| Khandelwal, M | 1 |
| Silver, RM | 1 |
| Le Gal, G | 1 |
| Keely, E | 1 |
| Rosene-Montella, K | 1 |
| Walker, M | 1 |
| Wells, PS | 2 |
| Ferrazzi, EM | 1 |
| Gervasi, MT | 1 |
| Simioni, P | 1 |
| Seed, PT | 1 |
| Lefkou, E | 1 |
| Lindqvist, PG | 1 |
| Andersen, AS | 1 |
| Berthelsen, JG | 1 |
| Bergholt, T | 1 |
| Norrad, RS | 1 |
| Salehian, O | 1 |
| Eldor, A | 1 |
| Ebina, Y | 1 |
| Yamada, H | 1 |
| Kato, EH | 1 |
| Yamamoto, R | 1 |
| Sakuragi, N | 1 |
| Fujimoto, S | 1 |
| Jacobsen, AF | 1 |
| Qvigstad, E | 1 |
| Sandset, PM | 1 |
| Gattens, M | 1 |
| Khamashta, M | 1 |
| Almeida, A | 1 |
| Barbour, LA | 1 |
| Oja, JL | 1 |
| Schultz, LK | 1 |
| Koren, G | 1 |
| Krafft, A | 1 |
| Bauersachs, RM | 1 |
| Dudenhausen, J | 1 |
| Faridi, A | 1 |
| Fischer, T | 1 |
| Fung, S | 1 |
| Geisen, U | 1 |
| Harenberg, J | 2 |
| Herchenhan, E | 1 |
| Keller, F | 1 |
| Kemkes-Matthes, B | 1 |
| Spannagl, M | 1 |
| Thaler, CJ | 1 |
| Rowlands, S | 1 |
| Lahoud, R | 1 |
| Hertzberg, M | 1 |
| Nicholl, M | 1 |
| Pettilä, V | 1 |
| Kaaja, R | 1 |
| Leinonen, P | 1 |
| Ekblad, U | 1 |
| Kataja, M | 1 |
| Ikkala, E | 1 |
| Huhle, G | 1 |
| Geberth, M | 1 |
| Hoffmann, U | 1 |
| Heene, DL | 1 |
| Chung, TS | 1 |
| Kim, SC | 1 |
| Bremme, K | 1 |
| van Rooijen, M | 1 |
| Yu, A | 1 |
| Blombäck, M | 1 |
| Moll, S | 1 |
| Bahlmann, F | 1 |
| Peetz, D | 1 |
| Savvidis, S | 1 |
| Himmrich, L | 1 |
| Klotz, M | 1 |
| Ismail, SK | 1 |
| Norris, L | 1 |
| O'Shea, S | 1 |
| Higgins, JR | 1 |
| Parent, F | 1 |
| Deruelle, P | 1 |
| Sanchez, O | 1 |
| Meyer, G | 1 |
| Girard, P | 1 |
| Jilwan, F | 1 |
| Boyer-Neumann, C | 1 |
| Wolf, M | 1 |
| Simonneau, G | 1 |
| Lykke, JA | 1 |
| Grønlykke, T | 1 |
| Langhoff-Roos, J | 2 |
| Jensen, HH | 1 |
| Søgaard, K | 1 |
| Grande, P | 1 |
| Powrie, R | 1 |
| Borg, JY | 1 |
| Rodger, M | 1 |
| Talbot, DJ | 1 |
| Stinson, J | 1 |
| Backe, SK | 1 |
| Lyons, GR | 1 |
| Smith, MP | 2 |
| Steer, PJ | 2 |
| Savidge, G | 1 |
| Opara, E | 1 |
| Gile, J | 1 |
| Zaidi, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Clinical Trial of Using Preconceptional Enoxaparin AND Low Dose Aspirin 81mg in Patient With Antiphospholipid Syndrome(APS)[NCT01661439] | 316 participants (Anticipated) | Observational | 2012-03-31 | Recruiting | |||
| anti10a Levels in Women Treated With LMWH in the Postpartum Period for Preventing Vein Thrombosis Events: A Comparison of Two Doses[NCT02856295] | Phase 4 | 136 participants (Actual) | Interventional | 2021-11-20 | Completed | ||
| TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.[NCT00967382] | Phase 3 | 292 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for dalteparin and Cardiovascular Pregnancy Complications
| Article | Year |
|---|---|
New frontiers with bemiparin: use in special populations.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Child; Female; Fibrinolytic Agents; Heparin, Low-Mol | 2010 |
Pregnancy outcome in a pregnant patient with idiopathic Pulmonary Arterial Hypertension: a case report and review of the literature.
Topics: Adult; Anticoagulants; Cesarean Section; Echocardiography; Enoxaparin; Familial Primary Pulmonary Hy | 2018 |
Risk Assessment and Treatment Guide for Obstetric Thromboprophylaxis: Comprehensive Review of Current Guidelines.
Topics: Anticoagulants; Enoxaparin; Female; Heparin; Humans; Postpartum Period; Practice Guidelines as Topic | 2019 |
Surgical Management of Placenta Accreta Spectrum.
Topics: Anticoagulants; Cesarean Section; Enoxaparin; Female; Gestational Age; Humans; Hysterectomy; Magneti | 2018 |
[Treatment of venous thromboembolism].
Topics: Administration, Oral; Adult; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Hepar | 2000 |
Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy.
Topics: Adult; Anticoagulants; Dalteparin; Female; Humans; Postpartum Hemorrhage; Pregnancy; Pregnancy Compl | 2019 |
The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy.
Topics: Abortion, Habitual; Analgesia, Epidural; Anticoagulants; Bone Density; Dalteparin; Female; Guideline | 2002 |
Low-molecular-weight heparins during pregnancy.
Topics: Anticoagulants; Dalteparin; Female; Heparin, Low-Molecular-Weight; Humans; Maternal-Fetal Exchange; | 2005 |
16 trials available for dalteparin and Cardiovascular Pregnancy Complications
| Article | Year |
|---|---|
Low molecular weight heparin treatment in pregnant women with a mechanical heart valve prosthesis.
Topics: Adult; Coumarins; Female; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Hydrocephalus; Nadro | 2007 |
Placental Pathological Findings following Adjusting Enoxaparin Dosage in Thrombophilic Women: Secondary Analysis of a Randomized Controlled Trial.
Topics: Adolescent; Adult; Anticoagulants; Data Interpretation, Statistical; Drug Administration Schedule; E | 2019 |
Randomized controlled study of pre-conception thromboprophylaxis among patients with recurrent spontaneous abortion related to antiphospholipid syndrome.
Topics: Abortion, Habitual; Adult; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Egypt; Eno | 2016 |
A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves.
Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Female; Heart Valve Diseases; Heart Valve Prosthesis; | 2011 |
Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial.
Topics: Abruptio Placentae; Adult; Enoxaparin; Female; Humans; Pilot Projects; Pregnancy; Pregnancy Complica | 2010 |
Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial.
Topics: Anticoagulants; Aspirin; Cohort Studies; Disease Progression; Enoxaparin; Female; Follow-Up Studies; | 2011 |
Anti-Xa activity with low-molecular-weight heparin, enoxaparin, during pregnancy in women with mechanical heart valves.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Heart Valve Prosthesis; Heparin, Lo | 2002 |
Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder.
Topics: Aspirin; Birth Weight; Enoxaparin; Female; Fetal Death; Folic Acid; Heparin, Low-Molecular-Weight; H | 2004 |
Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin.
Topics: Adult; Cesarean Section; Enoxaparin; Female; Fibrinolytic Agents; Humans; Osteoporosis; Patient Sele | 2004 |
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D | 2001 |
Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial.
Topics: Adult; Dalteparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Pregnancy; Pregnancy Complicatio | 2014 |
Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event.
Topics: Adult; Cohort Studies; Dalteparin; Female; Fibrinolytic Agents; Humans; Middle Aged; Pregnancy; Preg | 2003 |
A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation.
Topics: Abortion, Spontaneous; Adult; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Female; | 2004 |
Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.
Topics: Adult; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 2007 |
Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy.
Topics: Adult; Dalteparin; Demography; Female; Fractures, Bone; Hemorrhage; Heparin; Heparin, Low-Molecular- | 1999 |
Tinzaparin sodium for thrombosis treatment and prevention during pregnancy.
Topics: Female; Fibrinolytic Agents; Gestational Age; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Preg | 2004 |
86 other studies available for dalteparin and Cardiovascular Pregnancy Complications
| Article | Year |
|---|---|
Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium.
Topics: Anticoagulants; Female; Fibrinolytic Agents; Heparin; Humans; Nadroparin; Pregnancy; Pregnancy Compl | 2010 |
[Position of Experts Panel of the Polish Gynecological Society in the application of low molecular weight heparin - nadroparin calcium (Fraxiparine) in obstetrics and gynecology].
Topics: Anticoagulants; Female; Fibrinolytic Agents; Gynecology; Humans; Nadroparin; National Health Program | 2011 |
Thrombosis of a prosthetic aortic valve during pregnancy despite therapeutic dosage of Nadroparin.
Topics: Adult; Aortic Valve; Female; Heart Valve Prosthesis; Heparin; Heparin, Low-Molecular-Weight; Humans; | 2004 |
Pregnancy and Takayasu's arteritis of the pulmonary artery.
Topics: Adult; Anticoagulants; Female; Humans; Methylprednisolone; Nadroparin; Pregnancy; Pregnancy Complica | 2005 |
Delayed hypersensitivity to low-molecular-weight heparin (LMWH) in pregnancy.
Topics: Adult; Anticoagulants; Cortisone; Drug Eruptions; Female; Fibrinolytic Agents; Follow-Up Studies; Fo | 2007 |
[Thromboembolism prophylaxis in pregnancy and labor].
Topics: Anticoagulants; Drug Administration Schedule; Female; Heart Valve Prosthesis; Hemostasis; Humans; Na | 1996 |
Is there a safe anticoagulation protocol for pregnant women with prosthetic valves?
Topics: Adult; Anticoagulants; Female; Fetal Death; Heart Valve Prosthesis; Heparin; Humans; Nadroparin; Obs | 1998 |
Low-molecular-weight heparin and thromboembolism in pregnancy.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin, Low-Molecular-Weight; | 1999 |
Does low molecular weight heparin really protect against prosthetic valve thrombosis during pregnancy with strict anti-Xa monitoring?
Topics: Anticoagulants; Enoxaparin; Female; Heart Valve Diseases; Heart Valve Prosthesis; Heparin, Low-Molec | 2021 |
A Pregnant Woman With Shortness of Breath.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Anticoagulants; Cesarean Section; Dyspnea; Echocardio | 2021 |
[Anticoagulation's problematic during pregnancy in carriers of mechanical heart prosthesis].
Topics: Abortion, Spontaneous; Acenocoumarol; Adult; Algeria; Anticoagulants; Enoxaparin; Female; Heart Valv | 2018 |
Enoxaparin administration within 24 hours of caesarean section: a 6-year single-centre experience and patient outcomes.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complicati | 2019 |
Effectiveness and safety of thromboprophylaxis with enoxaparin for prevention of pregnancy-associated venous thromboembolism.
Topics: Adult; Blood Coagulation; Dose-Response Relationship, Drug; Enoxaparin; Female; Fibrinolytic Agents; | 2019 |
Thromboprophylaxis in pregnant women: For whom and which LMWH dosage?
Topics: Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Comp | 2019 |
Pregnancy outcomes compared in women with mechanical heart valve replacements anticoagulated with warfarin and enoxaparin in pregnancy.
Topics: Anticoagulants; Cross-Over Studies; Enoxaparin; Female; Heart Valve Prosthesis; Heart Valves; Humans | 2012 |
How I treat heterozygous hereditary antithrombin deficiency in pregnancy.
Topics: Adult; Antithrombin III; Antithrombin III Deficiency; Drug Administration Schedule; Enoxaparin; Fema | 2013 |
[Takayasu's arteritis in pregnancy--a case report].
Topics: Antihypertensive Agents; Cesarean Section; Enoxaparin; Female; Humans; Infant, Newborn; Male; Pregna | 2014 |
Oral anticoagulation with rivaroxaban during pregnancy: a case report.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Drug Substitution; | 2014 |
Changes in thrombin generation and D-dimer concentrations in women injecting enoxaparin during pregnancy and the puerperium.
Topics: Adolescent; Adult; Anticoagulants; Black People; Caribbean Region; Enoxaparin; Female; Fibrin Fibrin | 2014 |
Pregnancy in a woman with pulmonary hypertension: favorable outcome with intravenous treprostinil.
Topics: Adult; Anticoagulants; Antihypertensive Agents; Cesarean Section; Enoxaparin; Epoprostenol; Female; | 2015 |
Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
Topics: Adult; Anticoagulants; Antithrombin III; Body Mass Index; Body Weight; Dalteparin; Enoxaparin; Femal | 2008 |
Acute myocardial infarction in pregnancy.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Apgar Score; Aspirin; Cesarean Section; Coron | 2008 |
Acenocoumarol and pregnancy outcome in a patient with mitral valve prosthesis: a case report.
Topics: Acenocoumarol; Adult; Anticoagulants; Enoxaparin; Female; Heart Valve Prosthesis; Humans; Male; Mitr | 2009 |
Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin.
Topics: Anticoagulants; Delivery, Obstetric; Drug Administration Schedule; Drug Monitoring; Enoxaparin; Fema | 2009 |
Obstetric patient on Lovenox therapy: evidence of heparin activity at 24 hours.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; Thro | 2010 |
[Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery].
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anticoagulants; Cesarean Section; Emergencies; | 2010 |
Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia.
Topics: Adult; Anticoagulants; Cardiopulmonary Bypass; Echocardiography, Transesophageal; Embolectomy; Enoxa | 2010 |
Pulmonary embolectomy in heparin-induced thrombocytopenia and thrombosis? Safety of heparin use.
Topics: Anticoagulants; Cardiopulmonary Bypass; Embolectomy; Enoxaparin; Female; Fondaparinux; Heart Arrest, | 2010 |
A case of superior sagittal sinus thrombosis in pregnancy despite prophylactic antenatal heparin.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascula | 2010 |
Recurrent miscarriages: caution regarding development of clinical trials using low molecular weight heparin and pregnancy.
Topics: Abortion, Habitual; Adult; Anticoagulants; Clinical Trials as Topic; Dose-Response Relationship, Dru | 2011 |
Fixed dosing regimes of enoxaparin for thromboprophylaxis do not reliably achieve target anti-Xa levels in women of normal weight during pregnancy.
Topics: Adult; Anticoagulants; Body Weight; Enoxaparin; Factor Xa; Female; Humans; Pregnancy; Pregnancy Comp | 2011 |
Maternal cardiovascular hemodynamics in a patient with mitral prosthetic heart valve evaluated with impedance cardiography and echocardiography.
Topics: Adult; Anticoagulants; Cardiography, Impedance; Diagnosis, Differential; Echocardiography; Enoxapari | 2011 |
Pulmonary arterial hypertension in the setting of pregnancy: a case series and standard treatment approach.
Topics: Adult; Algorithms; Anticoagulants; Antihypertensive Agents; Bosentan; Enoxaparin; Epoprostenol; Fema | 2012 |
Successful maternal-foetal outcome using nitric oxide and sildenafil in pulmonary hypertension with atrial septal defect and HIV infection.
Topics: Anti-HIV Agents; Anticoagulants; Enoxaparin; Female; Heart Septal Defects, Atrial; HIV Infections; H | 2012 |
Anticoagulation of pregnant women with mechanical heart valves.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Heart Valve Prosthesis; Hep | 2003 |
Anticoagulation with prosthetic cardiac valves.
Topics: Anticoagulants; Enoxaparin; Female; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hum | 2003 |
Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascula | 2003 |
Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment.
Topics: Adult; Case-Control Studies; Enoxaparin; Female; Humans; Lipoproteins; Placenta; Placental Circulati | 2005 |
Budd-Chiari syndrome, systemic lupus erythematosus, and secondary antiphospholipid antibody syndrome in pregnancy.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Budd-Chiari Syndrome; Cholecystectom | 2005 |
Determination of anti-Xa levels in pregnant women treated with low molecular weight heparins for prevention of recurrent venous thromboembolism: a case report and review of the literature.
Topics: Adult; Disease Progression; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Heparin, Low-Molecu | 2008 |
Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cohort Studies; Enoxaparin; Female | 2008 |
[Acute myocardial infarction in pregnancy of 39 week treated with fibrinolysis].
Topics: Adult; Cardiac Catheterization; Enoxaparin; Female; Fibrinolytic Agents; Humans; Infant, Newborn; My | 2008 |
[Stents, antiplatelet therapy, and surgery].
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cesarean Section; Enoxaparin; Female | 2008 |
Low molecular weight heparin for obstetric thromboprophylaxis.
Topics: Drug Costs; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Complica | 1994 |
The use of low molecular weight heparin for thromboprophylaxis in pregnancy.
Topics: Adult; Dose-Response Relationship, Drug; Enoxaparin; Female; Gestational Age; Heparin; Humans; Pregn | 1994 |
Heparin-induced skin reaction due to two different preparations of low molecular weight heparin (LMWH)
Topics: Adult; Dalteparin; Drug Eruptions; Enoxaparin; Erythema; Female; Femoral Vein; Humans; Iliac Vein; P | 1993 |
Thrombocytopenia, antithrombin deficiency and extensive thromboembolism in pregnancy: treatment with low-molecular-weight heparin.
Topics: Adult; Antithrombin III; Antithrombin III Deficiency; Enoxaparin; Female; Fetal Death; Heparin; Huma | 1995 |
Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies.
Topics: Adult; Antiphospholipid Syndrome; Enoxaparin; Female; Fibrinolytic Agents; Humans; Labor, Obstetric; | 1996 |
Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.
Topics: Anticoagulants; Bone Density; Cohort Studies; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Pregn | 1997 |
Internal jugular vein thrombosis in patients with ovarian hyperstimulation syndrome.
Topics: Adult; Anticoagulants; Enoxaparin; Factor V; Female; Humans; Jugular Veins; Ovarian Hyperstimulation | 1998 |
[Deep venous thrombosis during pregnancy: long-term treatment with low molecular weight heparin].
Topics: Adult; Dose-Response Relationship, Drug; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; | 1999 |
Low molecular weight heparin for thromboprophylaxis during caesarean section.
Topics: Adult; Antibodies; Blood Coagulation; Cesarean Section; Delivery, Obstetric; Enoxaparin; Factor Xa; | 1999 |
Low-molecular-weight heparin for prosthetic heart valves: treatment failure.
Topics: Adult; Aged; Anticoagulants; Aortic Valve; Contraindications; Echocardiography; Enoxaparin; Female; | 2000 |
Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy.
Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Gestational Age; Humans; Pregnancy | 2000 |
A complication in anticoagulation using low-molecular weight heparin in a patient with a mechanical valve prosthesis. A case report.
Topics: Adult; Anticoagulants; Dilatation and Curettage; Enoxaparin; Female; Heart Valve Prosthesis; Heart V | 2000 |
Deep vein thrombosis during enoxaparin prophylactic treatment in a young pregnant woman homozygous for factor V Leiden and heterozygous for the G127-->a mutation in the thrombomodulin gene.
Topics: Adult; Anticoagulants; Enoxaparin; Factor V; Female; Humans; Point Mutation; Pregnancy; Pregnancy Co | 2000 |
Use of enoxaparin in a pregnant woman with a mechanical heart valve prosthesis.
Topics: Administration, Cutaneous; Adult; Anticoagulants; Aortic Valve; Contraindications; Enoxaparin; Femal | 2001 |
Enoxaparin treatment in women with mechanical heart valves during pregnancy.
Topics: Adult; Antibodies; Anticoagulants; Aspirin; Enoxaparin; Factor Xa; Female; Heart Valve Diseases; Hea | 2001 |
Branch retinal artery occlusion as a clinical manifestation of hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome) in pregnancy.
Topics: Adult; Dalteparin; Echocardiography; Embolization, Therapeutic; Female; Fibrinolytic Agents; Humans; | 2018 |
A case report of pulmonary arterial hypertension in pregnancy and complications of anticoagulation therapy.
Topics: Adult; Anticoagulants; Antihypertensive Agents; Cardiovascular Agents; Dalteparin; Epoprostenol; Fem | 2018 |
Recurrent cerebral ischaemia in a pregnant woman with patent foramen ovale II° and thrombophilia.
Topics: Adult; Anticoagulants; Brain Ischemia; Dalteparin; Female; Foramen Ovale, Patent; Humans; Injections | 2014 |
TIPPing practice away from anticoagulation in pregnancy.
Topics: Dalteparin; Female; Fibrinolytic Agents; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; | 2014 |
Dalteparin for pregnant women with thrombophilia.
Topics: Dalteparin; Female; Fibrinolytic Agents; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; | 2015 |
Dalteparin for pregnant women with thrombophilia.
Topics: Dalteparin; Female; Fibrinolytic Agents; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; | 2015 |
Dalteparin for pregnant women with thrombophilia.
Topics: Dalteparin; Female; Fibrinolytic Agents; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; | 2015 |
Dalteparin for pregnant women with thrombophilia - authors' reply.
Topics: Dalteparin; Female; Fibrinolytic Agents; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; | 2015 |
Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin.
Topics: Adult; Anticoagulants; Cesarean Section; Dalteparin; Female; Fetal Growth Retardation; Fibrinolytic | 2010 |
Management of severe mitral stenosis during pregnancy.
Topics: Adult; Anticoagulants; Catheterization; Dalteparin; Drug Therapy, Combination; Echocardiography, Dop | 2011 |
Thromboprophylaxis with low molecular weight heparin in thrombophilia-complicated pregnancy.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Dalteparin; Female; Humans; Pregnancy; Pregnancy C | 2002 |
Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy.
Topics: Acute Disease; Adult; Anticoagulants; Dalteparin; Factor Xa; Female; Humans; Norway; Pregnancy; Preg | 2003 |
The problem of risk assessment and prophylaxis of venous thromboembolism in pregnancy.
Topics: Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2007 |
Thromboembolism treated with low molecular weight heparin in a pregnancy complicated by major placenta praevia: a case report.
Topics: Adult; Cesarean Section; Dalteparin; Female; Humans; Male; Molecular Weight; Placenta Previa; Pregna | 1997 |
Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin.
Topics: Adult; Anticoagulants; Antithrombins; Dalteparin; Female; Heparin; Hirudin Therapy; Humans; Lupus Er | 2000 |
Drug eruption due to low molecular weight heparin.
Topics: Adult; Dalteparin; Drug Eruptions; Female; Fibrinolytic Agents; Humans; Injections, Subcutaneous; Pr | 2000 |
Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy.
Topics: Adult; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Gestational Age; Heparin; Humans; P | 2001 |
A low-molecular-weight heparin preparation contraindicated during pregnancy.
Topics: Adult; Anticoagulants; Benzyl Alcohol; Contraindications; Dalteparin; Female; Humans; Infant; Pregna | 2001 |
[Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy].
Topics: Adolescent; Adult; Antithrombin III; Dalteparin; Dose-Response Relationship, Drug; Female; Fibrin Fi | 2002 |
Weight-adjusted LMWH prophylaxis provides more effective thrombin inhibition in morbidly obese pregnant women.
Topics: Adult; Body Weight; Cohort Studies; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Huma | 2014 |
Safety of therapeutic doses of tinzaparin during pregnancy.
Topics: Adult; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Comp | 2015 |
Treatment of deep venous thrombosis in pregnant women.
Topics: Adult; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Gestatio | 2008 |
[Thrombolytic therapy in pregnant woman with pulmonary embolism].
Topics: Adult; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Comp | 2009 |
Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile.
Topics: Adolescent; Adult; Canada; Cohort Studies; Europe; Female; Fibrinolytic Agents; Heparin, Low-Molecul | 2011 |
Anticoagulation with Tinzaparin for women with mechanical valves in pregnancy: a retrospective case series.
Topics: Adult; Anticoagulants; Female; Fibrinolytic Agents; Heart Valve Prosthesis; Heparin, Low-Molecular-W | 2013 |
High-dose tinzaparin in pregnancy and the need for urgent delivery.
Topics: Adult; Anesthesia, Obstetrical; Anticoagulants; Female; Fibrinolytic Agents; Heparin, Low-Molecular- | 2002 |
Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study.
Topics: Adult; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight | 2004 |
Inferior vena cava filter thrombo-prophylaxis in high-risk twin pregnancy.
Topics: Adult; Anticoagulants; Combined Modality Therapy; Female; Fibrinolytic Agents; Heparin; Heparin, Low | 2007 |